<DOC>
	<DOCNO>NCT02592317</DOCNO>
	<brief_summary>The purpose study evaluate effect repeat dose JNJ-56021927 pharmacokinetics single-dose multiple cytochrome P450 ( CYP450 ) enzymes ( CYP3A4 , CYP2C9 , CYP2C19 , CYP2C8 ) transporter ( P-gp BRCP ) substrates participant castration-resistant prostate cancer ( CRPC ) .</brief_summary>
	<brief_title>A Study Evaluate Effect Multiple Doses JNJ-56021927 Pharmacokinetics Multiple Cytochrome P450 Transporter Substrates Participants With Castration-Resistant Prostate Cancer</brief_title>
	<detailed_description>This Phase 1 , multicenter , open-label study participant CRPC . The study consist Screening Phase determine eligibility , Pretreatment Phase , Treatment Phase , Follow-up Phase . The study design estimate magnitude effect JNJ-56021927 pharmacokinetics probe substrate . In vitro study indicate JNJ-56021927 active metabolite JNJ-56142060 ( M3 ) potential affect multiple cytochrome P450 ( CYP ) enzymes ( CYP3A4 , CYP2C9 , CYP2C19 , CYP2C8 ) drug transporter protein ( P-glycoprotein [ P-gp ] breast cancer resistance protein [ BRCP ] ) via inhibition induction . In human hepatocytes , JNJ 56021927 JNJ-56142060 ( M3 ) find inducer CYP3A4 . The induction CYP3A4 suggest JNJ-56021927 M3 induce CYP isozymes drug transporter ( eg , CYP2C P-gp via activation pregnane X receptor ) . The study design confirm vivo significance non-clinical finding .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms , Castration-Resistant</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Eastern Cooperative Oncology Group ( ECOG ) performance status score 0 , 1 , 2 Adenocarcinoma prostate Participants nonmetastatic castrationresistant prostate cancer ( NMCRPC ) metastatic castrationresistant prostate cancer ( mCRPC ) , opinion investigator may benefit treatment JNJ56021927 Surgically medically castrate , testosterone level &lt; 50 nanogram per deciliter ( ng/dL ) If participant treat gonadotropinreleasing hormone ( GnRHa ) ( ie , participant undergone bilateral orchiectomy ) , therapy must initiate least 4 week prior Cycle 1 Day 1 visit must continue throughout study Adequate bone marrow organ function define : Hemoglobin ( &gt; =9.0 g/dL , independent transfusion growth factor support within prior 7 day ) ; Absolute neutrophil count ( &gt; =1000/mm^3 independent growth factor support within prior 7 day ) ; Platelet count ( &gt; =75,000/mm^3 independent transfusion growth factor support within prior 7 day ) ; Serum albumin ( &gt; =3.0 g/dL ) ; Serum creatinine ( &lt; =1.5*upper limit normal ( ULN ) calculate creatinine clearance &gt; =50 mL/min/1.73m^2 ) ; Total bilirubin [ &lt; 1.5*ULN ( participant Gilbert 's Syndrome may enrol total bilirubin &lt; 4 mg/dL predominance indirect bilirubin &gt; =80 % total bilirubin ] ) ; Aspartate aminotransferase alanine aminotransferase ( &lt; =3.0*ULN ) ; Prothrombin time ( PT ) partial thromboplastin time ( PTT ) international normalize ratio ( INR ) ( PT &lt; =15 sec INR &lt; =1.2 PTT &lt; =40 sec ) . Known brain metastasis Chemotherapy immunotherapy treatment prostate cancer within 4 week Study Day 15 ( Cycle 1 Day 1 ) visit Prior treatment enzalutamide within 8 week first dose drug probe Therapies must discontinue substitute prior study visit Day 1 , must temporarily interrupt course study , include follow : ) Medications know low seizure threshold within 4 week Study Day 15 ( Cycle 1 Day 1 ) b ) Medications know induce inhibit drug metabolize enzyme ( CYP3A4 , CYP2C9 , CYP2C19 CYP2C8 ) transporter protein ( Pgp , BRCP , OATP1B1 , OATPB3 ) Participant know allergy , hypersensitivity , intolerance study drugs/drug probe excipients History seizure condition may predispose seizure within 12 month prior enrollment ( Study Day 1 ) ; brain arteriovenous malformation ; intercranial mass schwannoma meningioma cause edema mass effect Participants poor metabolizer genotype CYP2C9 ( *2 , *3 ) , CYP2C19 ( *2 , *3 , *4 , *8 )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>JNJ-56021927</keyword>
	<keyword>Prostatic Neoplasms , Castration-Resistant</keyword>
</DOC>